COMPARISON OF PROTEIN C INHIBITOR (PCI) BLOOD LEVELS IN WOMEN BEFORE STARTING SECOND GENERATION ORAL CONTRACEPTIVE PILLS AND AFTER THREE MONTHS OF USE

Namra Mahmood

Abstract


Background: Protein C inhibitor (PCI) is a serine protease inhibitor synthesized by the liver. Apart from its function of inhibiting activated protein C (APC), PCI also inhibits activated factor II, thrombin thrombomodulin complex, factor XIa, tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA). Increased level of PCI has been found in patients with thrombosis and women using oral contraceptives. The aim of the present study is to observe the effect of combined oral contraceptive pills on PCI levels after three months of its use and mean change from baseline.

Materials & Methods: Cross sectional descriptive study carried out at the pathology department, post graduate medical institute (PGMI) between 01/03/2018 to 02/03/2019 after taking ethical approval. Purposive convenience sampling technique was used. Blood sample of the study population was taken before the start of medication and after three menstrual cycles. Protein C inhibitor levels and demographic data was collected and analyzed using SPSS.

Results: Among total 54 females, the age of the women ranged from 22 years to 44 years with a mean of 29.5 ±5.3 years. The parity of the women ranged from 1 to 6 with a mean of 3.06 ±1.20. The baseline value of protein C inhibitor levels ranged from 1.1 to 8.7 mg/l with a mean of 5.84 ± 1.83 mg/l at baseline and increased upon 3-months follow-up to 8.2 to 20.1 mg/l with a mean of 12.74 ±3.29 mg/l. The women aged 29-35 years had highest of PCI levels at follow up with a mean of 13.47 ±4.28 mg/l and primiparas had highest increase among groups and it was statistically significant (p-value < 0.001).

Conclusion: It can be concluded from the study that use of the second generation oral contraceptive for 3 months is associated with induction of prothrombotic state by increase in the level of protein C inhibitor in the absence of any other prothrombotic conditions.


Keywords


Activated Protein C inhibitor; Protein C inhibitor; Thrombosis; Deep vein thrombosis; Oral contraceptives; Contraceptive agents.

Full Text:

PDF

References


Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, et all. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood. 2004;103(3):927-33. https://doi.org/10.1182/blood-2003-04-1285

Özkan D, Akar N. Analysis of Protein C Inhibitor/ SERPINA5. Turkish Journal of Clinics and Laboratory 2020;11(1):75-79. https://doi.org/10.18663/tjcl.645392

Yang H, Wahlmüller FC, Sarg B, Furtmüller M, Geiger M. A+-helix of protein C inhibitor (PCI) is a cell-penetrating peptide that mediates cell membrane permeation of PCI. J Biol Chem. 2015;290(5):3081-91. https://doi.org/10.1074/jbc.M114.581736

Einfinger K, Badrnya S, Furtmüller M, Handschuh D, Lindner H, Geiger M. Phospholipid Binding Protein C Inhibitor (PCI) Is Present on Microparticles Generated In Vitro and In Vivo. PLoS One 2015;10(11):e0143137. https://doi.org/10.1371/journal.pone.0143137

Meijers JC, Marquart JA, Bertina RM, Bouma BN, Rosendaal FR. Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis. Br J Haematol 2002;118(2):604-9. https://doi.org/10.1046/j.1365-2141.2002.03652.x

Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et all. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84(1):15-21. https://doi.org/10.1055/s-0037-1613960

Bremme K, Hamad RR, Berg E, Strandberg K, Stenflo J. The APC-PCI concentration as an early marker of activation of blood coagulation: a study of women on combined oral contraceptives. Thromb Res 2012;130(4):636-9. https://doi.org/10.1016/j.thromres.2011.11.006

Salman ST, Hussein AA, Saadi RK. Effect of Combined Oral Contraception on Coagulation Profiles in Women Attending Fertility Control Clinic in Baqubah City- Iraq. J Fac Med Bagdad 2018;60(1):47-51. https://doi.org/10.32007/jfacmedbagdad.60144

Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study. BMJ 2011;343:d6423-d6423. https://doi.org/10.1136/bmj.d6423

Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf 2014;5(5):201-13. https://doi.org/10.1177/2042098614548857

Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 2012;238(1):31-37. https://doi.org/10.1111/j.1365-2796.1995.tb00896.x

Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 2016;2(5599):199-205. https://doi.org/10.1136/bmj.2.5599.199

Jang YS, Lee ES, Kim YK. Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience. Obstet Gynecol Sci 2021;64(4):337-344. https://doi.org/10.5468/ogs.20374

Huisman MV, Büller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med. 2017;314(13):823-8. https://doi.org/10.1056/NEJM198603273141305




DOI: https://doi.org/10.46903/gjms/21.03.1285

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023. Namra Mahmood

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

JOURNAL INDEXING